These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 21070229

  • 1. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.
    Tfelt-Hansen P.
    Headache; 2011 Jan; 51(1):118-23. PubMed ID: 21070229
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.
    Tepper SJ, Cleves C.
    Curr Opin Investig Drugs; 2009 Jul; 10(7):711-20. PubMed ID: 19579177
    [Abstract] [Full Text] [Related]

  • 6. Molecule of the month. Telcagepant.
    Drug News Perspect; 2009 Mar; 22(2):115. PubMed ID: 19330169
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antimigraine efficacy of telcagepant based on patient's historical triptan response.
    Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD.
    Headache; 2011 Jan; 51(1):64-72. PubMed ID: 21054362
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries.
    Lynch JJ, Regan CP, Edvinsson L, Hargreaves RJ, Kane SA.
    J Cardiovasc Pharmacol; 2010 May; 55(5):518-21. PubMed ID: 20164785
    [Abstract] [Full Text] [Related]

  • 10. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.
    Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, Fan X, Aurora SK, Brandes JL, Fei K, Beebe L, Lines C, Krucoff MW.
    Headache; 2012 Feb; 52(2):224-35. PubMed ID: 22221076
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate.
    Edvinsson L, Linde M.
    Lancet; 2010 Aug 21; 376(9741):645-55. PubMed ID: 20416945
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
    Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L, Wright P, Greenberg SJ, AEGIS Investigator Study Group.
    Headache; 2007 Feb 21; 47(2):189-98. PubMed ID: 17300358
    [Abstract] [Full Text] [Related]

  • 17. Almotriptan: a review of pharmacology, clinical efficacy, and tolerability.
    Von S.
    Am J Manag Care; 2002 Feb 21; 8(3 Suppl):S74-9. PubMed ID: 11859907
    [Abstract] [Full Text] [Related]

  • 18. Randomized, controlled trial of telcagepant over four migraine attacks.
    Ho AP, Dahlöf CG, Silberstein SD, Saper JR, Ashina M, Kost JT, Froman S, Leibensperger H, Lines CR, Ho TW.
    Cephalalgia; 2010 Dec 21; 30(12):1443-57. PubMed ID: 20974601
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment.
    Tfelt-Hansen P.
    J Headache Pain; 2011 Jun 21; 12(3):275-80. PubMed ID: 21350792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.